Table 1. Clinical trials of concurrent TOP1 drugs with thoracic radiotherapy for NSCLC.
| Study description | No. of patients | Chemotherapy regimen | Radiation dose | Toxicity | Response rate |
|---|---|---|---|---|---|
| Phase II (43) | 24 | Irinotecan; 60-70 mg/m2, weekly ×6 | 60 Gy | Neutropenia esophagitis pneumonitis | 79% (19 PR) |
| Phase I/II (44) | 26 | Irinotecan; 30-60 mg/m2, weekly ×6 | 60 Gy | Esophagitis pneumonitis diarrhea | 77% (3 CR, 17 PR) |
| Phase II (45) | 12 | Irinotecan; 30-50 mg/m2, weekly ×6 | 60 Gy | Nausea/vomiting esophagitis | 58% (7 PR) |
| Phase I/II (46) | 26 | Irinotecan; 45 mg/m2, weekly ×6 |
60 Gy | Diarrhea esophagitis pneumonitis | 75% (2 CR, 16 PR) |
| Phase II (47) | 68 | Irinotecan + Cisplatin, Induction ×2, then weekly | 60 Gy | Neutropenia esophagitis pneumonitis | 63% (4 CR, 39 PR) |
| Phase I/II (48) | 12 | Irinotecan + Cisplatin, every 4 weeks ×3 | 60 Gy | Neutropenia diarrhea | 67% (8 PR) |
| Phase I/II (49) | 30 | Irinotecan weekly, 30-60 mg/m2, Carboplatin daily for 4 weeks | 60 Gy | Neutropenia esophagitis pneumonitis | 60% (3 CR, 15 PR) |
| Phase I/II (50) | 12 | Topotecan; 0.5-1 mg/m2, Days 1-5, 22-26 | 60 Gy | Nausea neutropenia esophagitis | 17% (2 CR) |
| Phase I/II (51) | 24 | Topotecan; 0.4 mg/m2, Daily, 21-42 days | 30-60 Gy | Neutropenia esophagitis | 43% (9 PR, 6 SD) |
NSCLC = non-small cell lung cancer; CR = complete response; PR = partial response; SD = stable disease.